<DOC>
	<DOCNO>NCT00117312</DOCNO>
	<brief_summary>Participants respond well Study FE200486 CS06 ( NCT00117949 ) give opportunity continue treatment degarelix clinical study FE200486 available market study discontinue . Study FE200486 CS06A provide knowledge long-term safety tolerability FE200486 .</brief_summary>
	<brief_title>Extension Study Investigating Long-Term Safety Tolerability Repeat Doses FE200486 Prostate Cancer Patients</brief_title>
	<detailed_description>The data include participant main study ( FE200486 CS06 ; NCT00117949 ) extension study FE200486 CS06A .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion entry study : Has give write consent study relate activity perform . A study related activity define procedure would perform normal management patient . Has sufficient testosterone suppression ( define withdrawal criterion FE200486 CS06 ) least 28 day . Any patient meeting follow exclusion criterion enter study : Has withdrawn Study FE200486 CS06 due adverse event , failure achieve least 28 day testosterone suppression , insufficient prostatespecific antigen ( PSA ) suppression define Study FE200486 CS06 absence concomitant rise testosterone level noncompliance protocol require procedure . Requires hormonal therapy neoadjuvant purpose . Requires treatment drug modify testosterone level function . Is consider candidate curative therapy , i.e. , radical prostatectomy radiotherapy , within 6 month Visit 1 . Has history severe asthma require daily treatment inhalation steroid , angioedema anaphylactic reaction . Has hypersensitivity towards component investigational product . Has cancer disease within last 10 year except prostate cancer , surgically remove basocellular squamous cell carcinoma skin . Has clinically significant neurologic , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , dermatological infectious disorder condition , include excessive alcohol drug abuse , may interfere trial participation may affect conclusion study , judge investigator . Any clinically significant laboratory abnormality , judgment investigator , would interfere patient 's participation study evaluation study result ( liver transaminase bilirubin must within normal limit ) . Has mental incapacity language barrier preclude adequate understanding cooperation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>